Patients with relapsing-remitting multiple sclerosis experience an accumulation of central nervous system damage and associated cognitive and physical disability progression. With the widespread use of disease modifying therapies, health plans have experienced improved clinical outcomes for MS together with increasing associated pharmacy-related expenses.
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune demyelinating disease of the central nervous system that has recently received significant focus from health plans and those who manage drug benefits. MS affects nearly 400,000 individuals in the United States and the majority of those affected by the disease have relapsing-remitting MS (RRMS). RRMS is characterized by clearly defined attacks, or relapses, of worsening neurological function with periods of partial to complete recovery between attacks. This form of MS occurs more often in women than men, with disease onset typically occurring between the ages of 20 and 50 years. Ultimately, patients with RRMS experience an accumulation of central nervous system damage and associated cognitive and physical disability progression. With the widespread use of disease modifying therapies (DMTs), health plans have experienced improved clinical outcomes for MS together with increasing associated pharmacy-related expenses.1
Prior to the 1993 launch of interferon beta-1b (IFNβ-1b), the first disease-modifying therapy for MS, there were only a few drugs available to treat MS exacerbations, and health plans were generally unconcerned with managing the cost of care associated with this illness. However, over the past 18 years, several additional DMTs have been developed to reduce relapse rates, improve short-term functionality, and modify the overall disease course. In 2010, prior to the launch of fingolimod (Gilenya), the first oral agent for the treatment of MS, there were 6 disease-modifying agents on the market: once-weekly intramuscular interferon beta-1a (IFNβ-1a), 3-times-weekly subcutaneous (SC) IFNβ-1a, 2 alternating daily SC IFNβ-1b products, once-daily SC glatiramer acetate (GA), and once-monthly intravenous natalizumab. Among these therapies, IFNβ formulations and GA have generally been regarded as the mainstays of first-line treatment.
The year 2012 saw the approval of the second oral agent for MS, teriflunomide (Aubagio). And this past month the US Food and Drug Administration approved dimethyl fumarate (Tecfidera) capsules for the treatment of adults with relapsing forms of MS. Like the other agents on the market, dimethyl fumarate has been shown to significantly reduce relapses and the development of brain lesions and slow disability progression over time.
Tecfidera, manufactured by Biogen Idec, is expected to be priced at a wholesale acquisition cost of $54,900 per patient per year. The price puts Tecfidera at a slight discount from the first multiple sclerosis oral agent, Gilenya, from Novartis, which has a list price of $60,000 per patient per year, but more than Aubagio from sanofi, which costs approximately $48,000 per year.2
Many experts expect Tecfidera to become one of the most commonly used MS drugs, taking share not only from newer pills like Gilenya and Aubagio, but also from older, commonly used injections such as Copaxone and Avonex. Although the medicines work in different ways, all of them basically aim to do the same thing: suppress the immune system, which appears in MS patients to attack the protective sheaths surrounding nerves.
Many doctors have been warehousing patients with early MS, waiting for this treatment to emerge. Because of this, financial analysts expect this drug to sell more than $1.77 billion in 2015 and $2.66 billion in 2017.2
The cost of treating MS has been escalating rapidly and for most payers it is the second-largest category of specialty drug spending, accounting for almost 30% of the specialty drug cost. With the introduction of the third oral agent to the market, it is likely that some of the traditional injectable therapies will be replaced by this oral agent at a higher cost. It is anticipated that payers will continue to manage the class with a comprehensive strategy of prior authorization (PA) of all of the MS agents, including the new oral products. Additionally, there are no data to support combination therapy of this agent with other products, so the PA processes at most plans will not support such combinations.
To date, no MS agent has truly emerged as a consensus “first-line” treatment, although this role is traditionally filled by glatiramer acetate and the interferons. However as the oral agents gain use and physicians gain experience with these agents, this may shift. Payers will need to be prepared to manage these changes of therapeutic direction as the care of this disease evolves.
REFERENCES
1. National MS Society. What we know about MS. http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/who-gets-ms/epidemiology-of-ms/index.aspx. Accessed April 16, 2013.
2. Matthew Herper. Biogen prices new MS pill at $55K, prepares for marketing battle. Forbes website. http://www.forbes.com/sites/matthewherper/2013/03/29/biogen-reveals-pricing-for-new-ms-drug-tecfidera/. Published March 29, 2013. Accessed April 15, 2013.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More